首页|胃癌患者血清胃泌素释放肽前体、鳞癌相关抗原和糖类抗原72-4的变化及意义

胃癌患者血清胃泌素释放肽前体、鳞癌相关抗原和糖类抗原72-4的变化及意义

扫码查看
目的 探讨胃癌患者血清胃泌素释放肽前体(ProGRP)、鳞癌相关抗原(SCC)及糖类抗原72-4(CA72-4)水平变化及临床意义。方法 选取68例胃癌患者(胃癌组)、37例胃部良性病变患者(胃部良性病变组)、30例健康受试者(非胃部疾病组)作为研究对象。比较3组研究对象入院时血清ProGRP、SCC、CA72-4水平;分析胃癌组患者血清ProGRP、SCC、CA72-4水平与病理参数的关系;对出院后胃癌组患者随访24个月,采用多因素Logistic回归分析明确胃癌患者随访预后的影响因素,绘制受试者工作特征(ROC)曲线并计算曲线下面积(AUC),分析血清ProGRP、SCC、CA72-4对胃癌患者随访期间死亡的预测效能。结果 胃癌组血清ProGRP、SCC、CA72-4水平高于胃部良性病变组和非胃部疾病组,胃部良性病变组血清ProGRP、CA72-4水平高于非胃部疾病组,差异有统计学意义(P<0。05);胃癌组中,TNM分期为Ⅲ~Ⅳ期、组织学分级为中低分化、有淋巴结转移患者血清ProGRP、CA72-4水平分别高于Ⅰ~Ⅱ期、高分化、无淋巴结转移患者,组织学分级为中低分化患者血清SCC水平高于高分化患者,差异有统计学意义(P<0。05)。随访24个月,胃癌组存活49例(存活组)、死亡19例(死亡组),死亡组患者入院时血清ProGRP、SCC、CA72-4水平均高于存活组,差异有统计学意义(P<0。05)。多因素Logistic回归分析结果显示,血清ProGRP、SCC、CA72-4均为胃癌患者随访预后的独立影响因素(P<0。05);血清ProGRP、SCC、CA72-4对胃癌患者随访期间死亡均有良好的预测效能(AUC=0。766、0。705、0。828),且三者联合的预测效能更佳(AUC=0。899)。结论 胃癌患者血清ProGRP、SCC、CA72-4水平异常升高(与TNM分期、组织学分级、淋巴结转移状态有关),三者联合检测对患者随访期间死亡具有很好的预测效能。
Changes and significance of serum pro-gastrin-releasing peptide,squamous cell carcinoma-related antigen and carbohydrateantigen 72-4 in patients with gastric cancer
Objective To investigate the changes and clinical significance of serum pro-gastrin-releasing peptide(ProGRP),squamous cell carcinoma-related antigen(SCC),and carbohydrate an-tigen 72-4(CA72-4)levels in patients with gastric cancer.Methods A total of 68 patients with gastric cancer(gastric cancer group),37 patients with benign gastric lesions(benign gastric lesion group),and 30 healthy subjects(non-gastric disease group)were selected as the study participants.Serum ProGRP,SCC,and CA72-4 levels were compared among the three groups on admission.The relationships of serum ProGRP,SCC,and CA72-4 levels with pathological parameters were analyzed in the gastric cancer group.Patients in the gastric cancer group were followed up for 24-month after discharge.Multivariate Logistic regression analysis was used to identify the influencing factors of prog-nosis in gastric cancer patients.Receiver operating characteristic(ROC)curves were plotted and the area under the curve(AUC)was calculated to analyze the predictive value of serum ProGRP,SCC,and CA72-4 for death during follow-up in gastric cancer patients.Results The serum levels of ProGRP,SCC,and CA72-4 in the gastric cancer group were higher than those in the benign gastric lesion group and the non-gastric disease group,and the serum levels of ProGRP and CA72-4 in the benign gastric lesion group were higher than those in the non-gastric disease group(P<0.05).In the gas-tric cancer group,patients with TNM stage Ⅲ to Ⅳ,moderately-lowly differentiated histological grade,and lymph node metastasis had higher serum levels of ProGRP and CA72-4 than those with stage Ⅰ to Ⅱ,high differentiation,and no lymph node metastasis.Patients with moderately-lowly differentiated histological grade had higher serum levels of SCC than those with high differentiated histological grade(P<0.05).After 24 months of follow-up,49 patients survived(survival group)and 19 patients died(death group)in the gastric cancer group.The serum levels of ProGRP,SCC,and CA72-4 in the death group were higher than those in the survival group on admission(P<0.05).Multivariate Logistic regression analysis showed that serum ProGRP,SCC,and CA72-4 were independent influencing factors for the prognosis of gastric cancer patients(P<0.05).Serum ProGRP,SCC,and CA72-4 had good predictive efficacy for death during follow-up in gastric cancer patients(AUC=0.766,0.705,0.828),and their combined predictive efficacy was better(AUC=0.899).Conclusion The serum levels of ProGRP,SCC,and CA72-4 that are related to TNM stage,histological grade,and lymph node metastasis in patients with gastric cancer are abnormally elevated,and their combined detection has good predictive efficacy for death during follow-up.

gastric cancerpro-gastrin-releasing peptidesquamous cell carcinoma-related antigencarbohydrate antigen 72-4pathological parameters

胡飞、张克昌、陈峰、童正喜、涂秀

展开 >

安徽医科大学附属滁州医院/滁州市第一人民医院检验科,安徽滁州,239000

胃癌 胃泌素释放肽前体 鳞癌相关抗原 糖类抗原72-4 病理参数

安徽省医学会急诊医学会分会2021年急诊临床研究项目

Ky2021012

2024

实用临床医药杂志
扬州大学,中国高校科技期刊研究会

实用临床医药杂志

CSTPCD
影响因子:1.543
ISSN:1672-2353
年,卷(期):2024.28(12)